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Alterations in Circulating Immune 
Cells in Neovascular Age-Related 
Macular Degeneration
Judith Lechner, Mei Chen, Ruth E. Hogg, Levente Toth, Giuliana Silvestri, 
Usha Chakravarthy & Heping Xu
Neovascular age-related macular degeneration (nAMD) is the leading cause of irreversible blindness 
in developed countries. Recent advances have highlighted the essential role of inflammation in the 
development of the disease. In addition to local retinal chronic inflammatory response, systemic 
immune alterations have also been observed in AMD patients. In this study we investigated the 
association between the frequency of circulating leukocyte populations and the prevalence as well 
as clinical presentations of nAMD. Leukocyte subsets of 103 nAMD patients (most of them were 
receiving anti-VEGF therapy prior to enrolment) and 26 controls were analysed by flow cytometry 
by relative cell size, granularity and surface markers. Circulating CD11b+ cells and CD16hiHLA-DR− 
neutrophils were significantly increased (P = 0.015 and 0.009 respectively) in nAMD when compared 
to controls. The percentage of circulating CD4+ T-cells was reduced in nAMD patients without 
subretinal fibrosis (P = 0.026) compared to patients with subretinal fibrosis. There was no correlation 
between the percentage of circulating leukocytes and the responsiveness to anti-VEGF therapy in 
nAMD patients. Our results suggest that higher levels of circulating CD11b+ cells and neutrophils 
are associated with nAMD and that reduced levels of CD4+ T-cells are associated with the absence of 
subretinal fibrosis in nAMD.
Age related macular degeneration (AMD) is the leading cause of blindness in the developed world in 
individuals above the age of 551,2. Visual acuity is usually unaffected in early stages of the disease, which 
is characterised by the presence of drusen which are deposits that occur in the outer retina and Bruch’s 
membrane-retinal pigment epithelial complex3. Visual loss occurs when there is degeneration and loss 
of photoreceptors, retinal pigment epithelium (RPE), and choriocapillaries (atrophic AMD) or when 
neovascularisation supervenes (neovascular AMD (nAMD)). When abnormal neovascular complexes are 
present under the retinal pigment epithelium this is referred to as type 1 choroidal neovascularisation 
(CNV). When these complexes invade the subretinal space these are referred to as type 2 membranes4. 
Neovascular complexes are also thought to arise de novo within the retina known as retinal angiomatous 
proliferation (RAP) and sometimes referred to as type 3 membranes. The neovascular lesions in RAP 
can fuse with choroidal new vessels (i.e., CNV)5.
Apart from aging, a plethora of risk factors have been shown to contribute to the development of 
AMD6,7. However, the pathogenesis of AMD remains incompletely understood. Compelling evidence 
suggests that inflammation plays a critical role in the aetiology of AMD8,9, and molecular dissection of 
immunological pathways to identify critical events will offer opportunities for the development of novel 
therapies. Genetic studies have identified an association of AMD risk with immune related genes, includ-
ing various complement related genes (CFH10, C311, C2 and CFB12) and chemokine receptor CX3CR113. 
Complement components and other inflammatory molecules have been found in drusen of AMD 
Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University 
Belfast, Belfast, UK. Correspondence and requests for materials should be addressed to H.X. (email: heping.xu@
qub.ac.uk)
received: 12 June 2015
accepted: 20 October 2015
Published: 17 November 2015
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 5:16754 | DOI: 10.1038/srep16754
patients14 and histological studies have detected macrophages in the vicinity of drusen15 as well as in 
retinal lesions16 in eyes from AMD patients, suggesting a local chronic inflammatory response in AMD.
In addition to the local inflammatory response, systemic immune alterations have also been observed 
in AMD patients. Increased serum levels of complement components17 and pro-inflammatory cytokines 
such as IL-1α , IL-1β and IL-1718 have been reported in patients with AMD. Changes in the expression of 
chemokine receptors (e.g. CCR2 and CX3CR1)19,20, complement regulatory proteins (e.g. CD46, CD59)21 
and CD20022 in circulating monocytes and lymphocytes have been observed in AMD patients. In addi-
tion, increased total white blood cell count was found to be associated with early AMD development23. 
More recently, a study has reported increased neutrophil/lymphocyte ratio in AMD patients compared 
to controls24. The involvement of systemic immune activation in AMD pathogenesis was further sup-
ported by a study from Nussenblatt et al.25 which showed that systemic immune suppression could alter 
the clinical course of nAMD and in some cases could reduce the monthly rate of intravitreal anti-VEGF 
injections to control disease progression when compared to pre-study injection rates or to injection rate 
in the control group. However, due to lack of knowledge in the detailed immune pathways involved in 
nAMD, more effective immune therapy has yet to be developed.
This research was performed to fully characterise the immunophenotype of nAMD and to understand 
whether a specific immunophenotype is related to certain clinical presentations or the responsiveness to 
anti-VEGF therapy in nAMD patients.
Results
General Information of Human Participants. In total, 129 participants were included in this study 
consisting of 26 controls and 103 nAMD patients. No significant differences were found between nAMD 
patients and controls regarding age, gender, family history of AMD, history of cardiovascular disease, 
history of hypertension, history of diabetes and BMI. The smoking habits were similar in both groups as 
well as the number of patients taking cardiovascular medication, vitamins and low dose aspirin (Table 1).
Most of the nAMD participants were receiving anti-VEGF therapy prior to enrolment and the aver-
age number of anti-VEGF injections received prior to blood collection was 14.3 ± 8.7 (range 0–38). No 
participant had received anti-VEGF treatment within 4 weeks prior to blood collection. There was no 
correlation between the number of anti-VEGF injections received and the percentage of lymphocytes 
(R2 = 0.16; P = 0.105, Fig. 1a), neutrophils (R2 = −0.09; P = 0.376, Fig. 1b), neutrophil/lymphocyte ratio 
(NLR) (R2 = −0.15; P = 0.137, Fig. 1c), CD11b+ cells (R2 = −0.11; P = 0.370, Fig. 1d), CD16hiHLA-DR− 
neutrophils (R2 = −0.15; P = 0.136, Fig. 1e), CD16hiHLA-DR−/(CD4 + CD8) ratio (R2 = −0.17; P = 0.105, 
Fig. 1f) and CD16hiHLA-DR−/CD8 ratio (R2 = −0.07; P = 0.490, Fig. 1g).
Leukocyte Subsets in nAMD Patients and Controls. White blood cells (leukocytes) can be 
divided into lymphocytes, monocytes and neutrophils based on their cell size and granularity using 
FSC/SSC plot in flow cytometry (Fig. 2a,e). The percentage of lymphocytes was significantly decreased 
in nAMD patients compared to age-matched healthy controls in both the univariate and multivariate 
All (n = 129)
Controls 
(n = 26)
nAMD 
(n = 103)
P value 
nAMD vs 
Control
Age (median (range)), years 79.1 (53–94) 76.7 (59–92) 79.5 (53–94) 0.0651
Female sex (number (%)) 70 (54) 12 (46) 58 (56) 0.3852
Have history of AMD (number (%)) 30 (23) 5 (19) 25 (24) 0.7962
Have history of cardiovascular disease (number (%)) 29 (22) 7 (27) 22 (21) 0.6012
Have history of hypertension (number (%)) 75 (58) 17 (65) 58 (56) 0.5062
Have history of diabetes (number (%)) 15 (12) 2 (8) 13 (13) 0.7342
Body Mass Index (mean ± SD) 26.4 (4.9) 27.1 (5.6) 26.1 (4.7) 0.3973
Smoking status 0.6332
Non-smoker (number (%)) 52 (40) 11 (42) 41 (40)
Former smoker (number (%)) 66 (51) 14 (54) 52 (50)
Current smoker (number (%)) 11 (9) 1 (4) 10 (10)
Taking cardiovascular medication (number (%)) 90 (87) 19 (73) 71 (69) 0.8132
Taking vitamins (number (%)) 25 (19) 2 (8) 23 (22) 0.1042
Taking low-dose aspirin (number (%)) 41(32) 4 (15) 37 (36) 0.0592
Table 1.  Demographic and clinical characteristics of nAMD patients and controls. SD: Standard 
deviation. 1Mann Whitney U test. 2Pearson’s chi-square test. 3Independent samples t-test.
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analysis (Table 2). Neutrophils were significantly increased in the univariate analysis (P = 0.025), how-
ever, after taking age and gender into account there was only a tendency of increased neutrophil per-
centage (P = 0.052) in nAMD compared to controls (Table  2). In addition, the NLR was significantly 
increased in the nAMD group compared to the control group in both univariate and multivariate anlaysis 
(Table  2). There was no association between the percentage of lymphocytes, neutrophils or NLR and 
other confounders.
After the initial analysis, leukocyte subsets were further analysed using specific cell surface anti-
gens, including CD4+ and CD8+ T-cells, CD19+ B-cells, CD56+ natural killer cells, CD11b+ myeloid 
cells, CD14+ monocytes and CD16hiHLA-DR− neutrophils (Fig.  2a–l). We detected two populations 
of CD16+HLA-DR− cells, CD16hiHLA-DR− and CD16loHLA-DR− (Fig. 2k,j). Back-gating of these two 
populations on a FSC/SSC plot showed that all the CD16hiHLA-DR− cells had a FSC/SSC profile of neu-
trophils (Supplemental Figure S1a, S1b), whereas the CD16loHLA-DR− cells had a FSC/SSC profile of 
lymphocytes (Supplemental Figure S1a, S1d). Furthermore, both CD16hiHLA-DR− and CD16loHLA-DR− 
cells were negative for CD14 (Supplemental Figure S1c, S1e). The results suggest that the CD16hiHLA-DR− 
cells are neutrophils and the CD16loHLA-DR− cells are likely nature killer cells26.
The percentage of CD11b+ cells was significantly increased in the univariate and multivariate anal-
ysis as well as the percentage of CD16hiHLA-DR− neutrophils in nAMD patients compared to controls 
(Table  2). There was a significant increase in the CD16hiHLA-DR−/(CD4 + CD8) ratio in the nAMD 
group in the univariate analysis (P = 0.031). On adjustment for age and gender, statistical significance 
was lost (Table 2). There was no association between the percentage of CD11b+ cells, CD16hiHLA-DR− 
neutrophils or CD16hiHLA-DR−/(CD4 + CD8) ratio and other confounders.
There was a tendency of increased CD16hiHLA-DR−/CD8 ratio in nAMD patients compared to con-
trols in the univariate and multivariate analysis adjusting for age and gender (Table  2, P = 0.051 and 
0.072 respectively). The CD16hiHLA-DR−/CD8 ratio was also significantly associated with history of 
cardiovascular disease and low-dose aspirin intake. Interestingly, when history of cardiovascular disease 
and low-dose aspirin intake were added to the multivariable logistic regression analysis, the increase in 
the CD16hiHLA-DR−/CD8 ratio in nAMD patients compared to controls was found to be significant 
(P = 0.041) (Table 2).
The average percentages of leukocyte sub-populations in control subjects in our study were simi-
lar to those reported previously27: lymphocytes: 30.7 ± 9.3% compared to 30.45 ± 7.8% in our study; 
monocytes: 8.9 ± 3.1% compared to 7.28 ± 1.88% in our study; CD16+ neutrophils: 60.0 ± 25.3% com-
pared to 57.8 ± 9.1% CD16hiHLA-DR− neutrophils in our study; CD19+ B-cells: 4.1 ± 2.0% compared to 
3.4 ± 2.16% in our study; T-cells and NK cells: 22.7 ± 6.7% compared to 21.3 ± 8.5% (CD4+, CD8+ and 
CD56+ cells) in our study.
Leukocyte Subsets and Responsiveness to Anti-VEGF Therapy. Of the 103 nAMD patients, 48 
(47%) responded completely to the anti-VEGF therapy, 52 (50%) partially responded to the therapy and 
3 patients (3%) did not respond to the therapy. Due to the limited number of non-responders in this 
study, this group was not included in the statistical analysis. No differences in leukocyte subsets were 
identified when comparing complete responders with partial responders (Supplemental Table S1).
Figure 1. The relationship between the number of anti-VEGF injections and different subsets of 
circulating immune cells. The number of anti-VEGF injections received by nAMD patients did not 
correlate with the percentage of lymphocytes (a), neutrophils (b), the NLR (c), with the percentage of 
CD11b+ cells (d), CD16hiHLA-DR− neutrophils (e), the CD16hiHLA-DR−/(CD4 + CD8) ratio (f) or the 
CD16hiHLA-DR−/CD8 ratio (g).
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Leukocyte Subsets and Subretinal Fibrosis. Among nAMD patients, subretinal fibrosis was 
present in 37 patients (36%). The level of CD4+ T-cells was significantly lower in patients without 
fibrosis (10.82%) than in patients with fibrosis (12.44%) in both the univariate and multivariate anal-
ysis (P = 0.026) (Table  3). The level of CD4+ T-cells was similar in nAMD patients with fibrosis and 
age-matched healthy controls (Table  3). The percentage of CD4+ T-cells was not associated with any 
other confounders. There was no difference in the level of other leukocyte subsets between patients with 
and without subretinal fibrosis (Table 3).
Leukocyte Subsets in Patients with CNV and RAP. Details regarding the type of neovascularisa-
tion were available for 79 out of 103 nAMD patients. Of those, 66 (84%) were diagnosed with CNV and 
13 (16%) were diagnosed with RAP. No significant differences were found in leukocyte subsets between 
CNV and RAP, although there was a tendency of increased percentage of CD11b+ cells in RAP patients 
compared to CNV patients (76.72% and 72.00% respectively; P = 0.082) (Table 4).
When the two groups were compared to the control group, RAP nAMD patients had a significantly 
increased percentage of CD11b+ cells in the univariate and multivariate analysis (P = 0.009 and 0.033 
respectively, Table 4). Patients with CNV had a tendency of increased percentage of CD11b+ cells in the 
univariate analysis (P = 0.086) and this p-value was found to be significant when age and gender were 
taken into account in the multivariate analysis (P = 0.046). Additionally, CNV patients had a significantly 
increased percentage of CD16hiHLA-DR− neutrophils when compared to controls in both the univariate 
and multivariate analysis (P = 0.027 and 0.015 respectively). While patients with RAP had the highest 
CD16hiHLA-DR− neutrophil percentage, the difference was not statistically significant when compared 
to controls (Table  4). The percentage of lymphocytes was lowest in RAP patients but the reduction 
did not reach statistical significance when compared to controls (P = 0.064) (Table  4). There were no 
Figure 2. Gating strategy used in flow cytometry analysis to detect different subsets of circulating 
immune cells. Sample data from a control (a–d,i,k) and a nAMD patient (e–h,j,l) are shown. Lymphocyte, 
monocyte and neutrophil populations were gated on a forward scatter (FSC)/side scatter (SSC) plot (a,e). 
Lymphocytes were then further gated to determine CD4+, CD8+ (b,f), CD19+ and CD56+ lymphocytes 
(c,g). Live cells were further gated to determine CD11b+ cells (d,h), CD14+ monocytes (i,j) and 
CD16hiHLA-DR− neutrophils (k,l).
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differences between CNV, RAP and controls in other leukocyte populations or neutrophil/lymphocyte 
ratios (Table 4).
Details regarding the type of CNV were available for 58 out of 66 CNV patients. Seven patients 
(12%) were diagnosed with classic CNV, 32 (55%) with occult CNV and 19 (33%) with a mixed phe-
notype. There were no differences in any of the leukocyte subsets between the three groups of CNV 
(Supplemental Table S2).
Discussion
Recent findings suggest that systemic immune alterations may play a role in the pathogenesis of AMD. In 
addition to increased levels of complement components and pro-inflammatory cytokines in the serum of 
AMD patients17,18, changes in leukocytes, especially monocytes have been reported in AMD20–22. In this 
study, we found that the percentages of circulating CD11b+ cells and CD16hiHLA-DR− neutrophils were 
significantly increased in nAMD patients when compared to controls. We further found a higher per-
centage of CD4+ T-cells in patients with subretinal fibrosis when compared to patients without subretinal 
fibrosis. We found no correlation between the percentage of circulating leukocytes and the responsive-
ness to anti-VEGF therapy in nAMD patients. Our observation may have important implications in 
future management of nAMD.
The leukocyte antigen CD11b is expressed on both neutrophils and monocytes. There was no signif-
icant difference in the percentage of CD14+ monocytes between nAMD patients and controls indicating 
that the increased percentage of CD11b+ cells is due to the increased percentage of CD16hiHLA-DR− 
neutrophils. Increased neutrophil/lymphocyte ratio in AMD patients has been observed by others24. The 
precise role of neutrophils in AMD pathogenesis remains elusive. Neutrophils are the most abundant leu-
kocytes in the blood and respond rapidly to inflammatory and infectious stimuli. Traditionally, neutro-
phils were considered as innate immune cells that engulf bacteria and phagocytose apoptotic cells during 
acute inflammation28. In recent years it has become evident that the complexity of neutrophil functions 
is far more widespread than previously thought and that they play an active role in many aspects of the 
innate immune response29. Activated neutrophils can produce pro-inflammatory cytokines such as IL-8 
Variables
Controls 
(mean ± SD) 
n = 26
nAMD 
(mean ± SD) 
n = 103
Univariate 
analysis Multivariate analysis (age and gender)
Multivariate analysis (age, gender, 
cardiovascular disease and aspirin 
intake)
P value 
nAMD vs 
Controls1
P value 
nAMD vs 
Controls2
Odds 
ratio
95% 
confidence 
interval for 
odds ratio
P value 
nAMD vs 
Controls3
Odds 
ratio
95% 
confidence 
interval for 
odds ratio
Cell subsets (FSC/SSC plot)
 Lymphocytes (%) 30.45 ± 7.82 26.51 ± 6.97 0.013 0.033 0.94 0.88–0.99
 Monocytes (%) 7.28 ± 1.88 7.85 ± 2.58 0.292
 Neutrophils (%) 59.80 ± 8.73 63.71 ± 7.60 0.025 0.052 1.06 1.00–1.12
 Neutrophil/Lymphocyte ratio 2.16 ± 0.84 2.66 ± 1.08 0.016 0.037 17.56 1.19–258.21
Cell subsets (CD antigens)
 CD14+ (%) 7.35 ± 1.95 7.61 ± 2.24 0.628
 CD4+ (%) 12.21 ± 3.92 11.46 ± 4.25 0.301
 CD8+ (%) 5.86 ± 2.96 5.06 ± 3.49 0.137
 CD19+ (%) 3.41 ± 2.16 2.78 ± 1.48 0.126
 CD56+ (%) 3.27 ± 1.66 3.46 ± 1.94 0.834
 CD11b+ (%) 67.40 ± 9.00 72.77 ± 7.68 0.006 0.015 1.08 1.01–1.14
 CD16hiHLA-DR− Neutrophils (%) 57.80 ± 9.05 63.19 ± 7.87 0.003 0.009 1.07 1.02–1.13
  CD16hiHLA-DR−/(CD4 + CD8) 
ratio 3.51 ± 1.49 4.42 ± 1.88 0.031 0.072 10.24 0.81–129.24
 CD16hiHLA-DR−/CD4 ratio 5.34 ± 2.34 6.34 ± 2.74 0.100
 CD16hiHLA-DR−/CD8 ratio 13.80 ± 11.28 19.82 ± 16.22 0.051 0.072 3.97 0.88–17.88 0.041 5.66 1.07–29.79
 CD16hiHLA-DR−/CD19 ratio 25.69 ± 21.26 32.14 ± 26.91 0.085
 CD16hiHLA-DR−/CD56 ratio 22.41 ± 11.25 25.75 ± 19.89 0.714
Table 2. Percentage of leukocyte populations and cell ratios in nAMD patients and controls. Bold 
P< 0.05; SD: Standard deviation. 1Independent samples t-test. 2Multivariable logistic regression; corrected 
for age and gender. 3Multivariable logistic regression; corrected for age, gender, cardiovascular disease and 
aspirin intake.
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and IL-1β , which can further recruit other immune cells30,31. Neutrophils can also stimulate T-cell activa-
tion through expression of MHC class II32,33. Indeed, neutrophils have been shown to promote inflamma-
tion in a number of human inflammatory diseases such as arthritis34 and atherosclerosis35. There is now 
increasing evidence that neutrophils also play an active role in angiogenesis36,37. Activated neutrophils 
produce proteases, in particular matrix metalloproteinase-9 (MMP-9), which degrade and remodel the 
extracellular matrix, a crucial process in angiogenesis38. Neutrophils are known to be involved in retinal 
angiogenesis in laser-induced CNV39, probably through disruption of the RPE barrier integrity by releas-
ing MMP-940. In addition, neutrophils can promote angiogenesis by releasing pro-angiogenic factors 
such as VEGF and IL-841. Furthermore, VEGF can recruit pro-angiogenic neutrophils that produce high 
levels of MMP-937.
Subretinal fibrosis develops in some patients with late stage nAMD as a result of subretinal haemor-
rhages and can cause irreversible central vision loss4. It is unknown why some patients develop subret-
inal fibrosis while others do not. In the present study we report that patients without subretinal fibrosis 
have a lower percentage of CD4+ T-lymphocytes (10.82%) when compared to patients who developed 
subretinal fibrosis (12.44%). Interestingly, patients who developed subretinal fibrosis had similar levels 
of CD4+ T-cells as controls (12.21%) suggesting lower levels of CD4 might reduce the risk of developing 
subretinal fibrosis. While the difference between patients with and without subretinal fibrosis was sta-
tistically significant (P = 0.026), the clinical relevance of such a small difference (1.6%) warrants further 
investigation. CD4+ T-cells have previously been linked to the formation of fibrosis in other tissues in 
human diseases and in animal models. Increased numbers of CD4+ cells have been found in the lungs 
of patients with lung fibrosis42, and in fibrotic kidneys of patients with IgA nephropathy43. Neutralisation 
of CD4+ T-cells decreased the formation of fibrosis in a mouse model of tail lymphedema44 and reduced 
the intensity of silica induced lung fibrosis45, although, other studies reported controversial results46. 
Recent discoveries have shown that different subsets of CD4+ cells have different roles in fibrosis with 
some subpopulations (Th17, Th2) displaying more pro-fibrotic properties while others (Th22) have 
more anti-fibrotic properties or a dual role with pro- and anti-fibrotic functions (Th9, Tregs)47. Th17 is 
reported to be associated with AMD48. Our results suggest that CD4 T-cells might be associated with 
the development of subretinal fibrosis, however further studies including larger number of patients are 
required to confirm those findings.
Variables
Controls 
(mean ± SD) 
n = 26
Fibrosis 
absent 
(mean ± SD) 
n = 66
Fibrosis 
present 
(mean ± SD) 
n = 37
Univariate 
analysis
Multivariate analysis (age and 
gender)
P value 
fibrosis 
absent vs 
present1
P value 
fibrosis 
absent 
vs 
present2
Odds 
ratio
95% 
confidence 
interval for 
odds ratio
Cell subsets (FSC/SSC plot)
 Lymphocytes (%) 30.45 ± 7.82 26.17 ± 7.4 27.11 ± 6.19 0.517
 Monocytes (%) 7.28 ± 1.88 8.09 ± 2.71 7.43 ± 2.32 0.215
 Neutrophils (%) 59.80 ± 8.73 63.80 ± 8.25 63.55 ± 6.37 0.869
 Neutrophil/Lymphocyte ratio 2.16 ± 0.84 2.75 ± 1.22 2.51 ± 0.77 0.515
Cell subsets (CD antigens)
 CD14+ (%) 7.35 ± 1.95 7.75 ± 2.39 7.35 ± 1.96 0.447
 CD4+ (%) 12.21 ± 3.92 10.82 ± 4.08 12.44 ± 4.37 0.042 0.026 37.08 1.53–899.43
 CD8+ (%) 5.86 ± 2.96 5.39 ± 3.8 4.51 ± 2.85 0.326
 CD19+ (%) 3.41 ± 2.16 2.95 ± 1.69 2.53 ± 1.07 0.249
 CD56+ (%) 3.27 ± 1.66 3.49 ± 1.57 3.42 ± 2.34 0.340
 CD11b+ (%) 67.40 ± 9.00 72.97 ± 8.47 72.48 ± 6.55 0.797
 CD16hiHLA-DR− Neutrophils (%) 57.80 ± 9.05 63.33 ± 8.7 62.95 ± 6.21 0.798
  CD16hiHLA-DR−/(CD4 + CD8) 
ratio 3.51 ± 1.49 4.60 ± 2.06 4.13 ± 1.56 0.462
 CD16hiHLA-DR−/CD4 ratio 5.34 ± 2.34 6.80 ± 3.07 5.65 ± 1.97 0.120
 CD16hiHLA-DR−/CD8 ratio 13.80 ± 11.28 19.10 ± 15.52 21.02 ± 17.48 0.381
 CD16hiHLA-DR−/CD19 ratio 25.69 ± 21.26 31.16 ± 27.45 33.55 ± 26.44 0.354
 CD16hiHLA-DR−/CD56 ratio 22.41 ± 11.25 22.91 ± 15.72 29.25 ± 23.86 0.274
Table 3. Percentage of leukocyte populations and cell ratios in patients with nAMD with and without 
subretinal fibrosis. Bold P < 0.05; SD: Standard deviation. 1Independent samples t-test. 2Multivariable 
logistic regression; corrected for age and gender.
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Neovascular AMD is currently treated with regular intravitreal injections of anti-VEGF agents, 
including ranibizumab (Lucentis, Genentech, San Francisco, CA), bevacizumab (Avastin, Roche, Basel, 
Switzerland) and more recently aflibercept (Eylea, Regeneron, Tarrytown, New York). However, up to 10% 
of patients do not respond to the treatment and approximately half of the patients only partially respond 
to the therapy49. As leukocytes are known to play important roles in nAMD and different leukocytes 
may produce different types of angiogenic growth factors (in addition to VEGF), we hypothesised that 
alterations in leukocyte subsets might be associated with response to anti-VEGF treatment. We found no 
differences in leukocyte levels between patients completely or partially responding to anti-VEGF ther-
apy, suggesting that immunophenotype is unlikely associated with the response to anti-VEGF therapy. 
However, additional studies including large numbers of patients are necessary to confirm those results. 
Predictors of treatment outcomes would be beneficial in performing the most appropriate treatment in 
the most cost effective way for each patient and would allow giving more accurate prognosis. A number 
of studies have searched for predictors of treatment response by looking at clinical and genetic factors49. 
However, a strong marker has not yet been identified thus far.
In this study, we found a significantly increased percentage of CD11b+ cells in both CNV patients and 
RAP patients, whereas the percentage of CD16hiHLA-DR− neutrophils was only increased statistically 
in patients with CNV but not RAP when compared to controls. However due to the small number of 
participants in the RAP group (n = 13), these results must be interpreted with caution. Further studies 
using larger patient samples are necessary to see whether alterations in circulating immune cells are 
related to a specific type of neovascularisation in nAMD.
There are a number of limitations in the current study. Firstly, there was a small difference in age 
between nAMD patients and controls although this was not statistically significant. The median age was 
higher in the nAMD group compared to controls (79.5 and 76.7 years respectively). Secondly patients 
were recruited at different times following diagnosis of nAMD. Consequently, some patients enrolled at 
an early stage of nAMD and classified as having no fibrosis, might still develop fibrosis during the course 
of the disease. Subdividing the nAMD group into CNV/RAP, fibrosis absent/present and complete/par-
tial responders was carried out as a secondary analysis and the study was not planned specifically to 
Univariate analysis Multivariate analysis (age and gender)
Variables
Controls 
(mean ± SD) 
n = 26
CNV 
(mean ± SD) 
n = 66
RAP 
(mean ± SD) 
n = 13
P 
value 
CNV 
vs 
RAP1
P value 
CNV vs 
RAP vs 
controls2
P value 
Bonferroni 
post hoc test
P value CNV 
vs RAP vs 
controls3
Odds 
ratio
95% 
confidence 
interval for 
odds ratio
Cell subsets (FSC/SSC plot)
 Lymphocytes (%) 30.45 ± 7.82 27.13 ± 7.32 24.62 ± 6.36 0.254 0.047 0.1614 0.0645
 Monocytes (%) 7.28 ± 1.88 7.84 ± 2.38 8.44 ± 4.02 0.468 0.382
 Neutrophils (%) 59.80 ± 8.73 63.28 ± 7.55 65.35 ± 8.01 0.373 0.075
 Neutrophil/Lymphocyte ratio 2.16 ± 0.84 2.62 ± 1.17 2.87 ± 0.96 0.329 0.055
Cell subsets (CD antigens)
 CD14+ (%) 7.35 ± 1.95 7.61 ± 2.05 8.45 ± 3.57 0.336 0.472
 CD4+ (%) 12.21 ± 3.92 11.88 ± 4.75 10.77 ± 3.02 0.600 0.614
 CD8+ (%) 5.86 ± 2.96 5.25 ± 3.66 4.69 ± 2.49 0.978 0.425
 CD19+ (%) 3.41 ± 2.16 2.86 ± 1.37 2.19 ± 1.23 0.117 0.110
 CD56+ (%) 3.27 ± 1.66 3.50 ± 2.16 3.39 ± 1.71 0.801 0.958
 CD11b+ (%) 67.40 ± 9.00 72.00 ± 7.92 76.72 ± 5.42 0.082 0.007 0.0864 0.0095 0.0464 0.0335 1.07 1.15 1.00 ± 1.14 1.01 ± 1.30
  CD16hiHLA-DR−  
Neutrophils (%) 57.80 ± 9.05 62.92 ± 8.09 63.26 ± 7.77 0.888 0.025 0.027
4 0.1665 0.0154 0.3045 1.08 1.05 1.01 ± 1.14 0.96 ± 1.15
  CD16hiHLA-DR−/(CD4 + CD8) 
ratio 3.51 ± 1.49 4.25 ± 1.92 4.51 ± 1.56 0.487 0.150
 CD16hiHLA-DR−/CD4 ratio 5.34 ± 2.34 6.26 ± 2.94 6.40 ± 2.16 0.595 0.317
 CD16hiHLA-DR−/CD8 ratio 13.80 ± 11.28 20.40 ± 18.82 17.00 ± 8.09 0.997 0.221
 CD16hiHLA-DR−/CD19 ratio 25.69 ± 21.26 31.21 ± 27.79 45.60 ± 40.21 0.131 0.083
 CD16hiHLA-DR−/CD56 ratio 22.41 ± 11.25 27.33 ± 23.06 23.06 ± 10.91 0.942 0.922
Table 4. Percentage of leukocyte populations and cell ratios in nAMD patients with CNV and RAP. Bold 
P < 0.05; SD: Standard deviation. 1Independent samples t-test. 2One-way ANOVA. 3Multinomial logistic 
regression corrected for age and gender. 4Controls vs CNV. 5Controls vs RAP.
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detect these associations (power < 80%), we recognise that the conclusions drawn from this part of the 
study are tentative and will require confirmation in a larger study. There are four times more cases 
enrolled in the study than controls which is the maximum imbalance acceptable for case-control studies 
and might affect the statistical analyses. Finally, patients enrolled in this study were receiving anti-VEGF 
treatment prior to enrolment which may have altered circulating immune cell levels although there was 
no correlation with the number of anti-VEGF injections received and the percentage of immune cells. 
Furthermore the drug in use in our study site was ranibizumab which is cleared more rapidly from the 
systemic circulation and has the least effect on serum VEGF levels when compared to other anti-VEGF 
agents50. Despite the limitations, the present study has uncovered novel systemic immune alterations in 
nAMD patients and might have important implications in the management of nAMD.
In summary, we show that neutrophils were increased in patients with nAMD suggesting increased 
systemic innate immune activation in nAMD patients. Our results also indicate that CD4+ T-cells may 
be related to the development of subretinal fibrosis in nAMD patients. Further studies about the role of 
neutrophils in nAMD and the role of CD4 T cells in subretinal fibrosis may advance our understanding 
in the immunopathogenesis of nAMD and uncover novel targets for therapy.
Methods
Study Participants. The study protocol was approved by the Research Ethics Committee of Queen’s 
University Belfast and Belfast Health and Social Care Trust  Research Ethics Committee, UK. The 
study procedures were performed in accordance with the tenets of the Declaration of Helsinki. Written 
informed consent was obtained from every participant.
All participants were recruited from the macular disease clinics in Belfast (Belfast Health and Social 
Care Trust, UK). Relatives and spouses, who attended the clinic with patients and who were without 
retinal disease (confirmed by fundus photography and optical coherence tomography (OCT)) were 
recruited as controls. All participants were above 53 years of age and structured questionnaires were 
used to ascertain a history of medical conditions, current medication, family history of AMD, smoking 
habits (current, ex-smoker, never smoker) and BMI. Patients with systemic inflammatory or autoimmune 
disease were excluded from the study as well as patients receiving steroid drug treatment. The diagno-
sis of nAMD was confirmed by an experienced ophthalmologist on clinical examination using fundus 
photography, fluorescein angiography and OCT. In this study most of the participants were receiving 
anti-VEGF therapy prior to enrolment. The number of anti-VEGF (ranibizumab, trade name Lucentis, 
Genentech, San Francisco, CA) injections received by each patient prior to blood collection was ascer-
tained from the medical records. Peripheral blood samples were drawn in tubes containing ethylenedi-
aminetetraacetic acid (EDTA) as anticoagulant between 9:00 and 12:00 am and processed within 3 hours 
of collection. Responsiveness to treatment was defined based on the participant achieving a fluid free 
macula at any stage during follow up. In addition the status of whether a patient was fluid free at the 
month 3 and month 6 examinations was also recorded. Participants were classified into the following 
3 categories: Complete responder: Resolution of leakage at any point in time during follow up; Partial 
responder: Exhibiting dependence of VEGF inhibitors but a fluid free macula was never achieved; Non 
responder: No morphological improvement or worsening.
Flow Cytometry of Human Blood Samples. Freshly drawn blood samples (30 μ l) were incubated 
with fluorochrome-labelled antibodies in a total volume of 100 μ l FACS buffer (PBS/1% fetal calf serum 
(FCS)) for 45 min in the dark at 4 °C. Red blood cells were lysed by incubating the sample with 2 ml 
of 1X red blood cell lysis solution (BD Biosciences, Oxford, UK) for 10 min at room temperature (RT). 
After thorough washes samples were fixed in 1% paraformaldehyde (PFA) for 30 min in the dark at 
4 °C. Samples were then washed and resuspended in PBS. All samples were examined by flow cytometry 
(FACS CANTO II; BD Biosciences), and data analysed blindly using the FlowJo software (version 10.07 
for Windows, Tree Star, Ashland, OR, USA). The following anti-human antibodies were used for identi-
fication of leukocyte subsets: CD14-APC-Cy7, CD19-FITC, CD16-Pacific Blue, CD56-PE, CD8-PE-Cy7, 
CD4-Pacific Blue, CD11b-APC (all from BD Biosciences, UK) and HLA-DR-PE (eBioscience, UK). Live 
cells were gated for further analysis of leukocyte subsets. Different subsets of leukocytes were identified 
by relative cell size and granularity (FSC/SSC) or cell surface markers (Fig. 1). The neutrophil/lymphocyte 
ratio (NLR) was calculated by dividing the percentage of neutrophils by the percentage of lymphocytes.
Statistical Analysis. Statistical analysis was performed using the Statistical Package for the Social 
Sciences, Windows version 21 (SPSS Inc, Armonk, NY). Categorical demographic and clinical data 
were compared using Pearson’s chi-square test. The distribution of continuous variables was assessed 
for normality using the Kolmogorov-Smirnov test and transformed if necessary. Normally distributed 
continuous samples were then compared using the Independent samples t-test or one-way ANOVA. If 
transformation failed to improve the distribution, Mann-Whitney U test was used for the comparisons. 
For the associations that were significant in the univariate analysis, multivariable logistic regression, 
using a generalised linear model, was performed to adjust for age and gender. All variables were also 
tested for association with family history of AMD, history of cardiovascular disease, history of hyper-
tension, history of diabetes, smoking habits, BMI, taking of cardiovascular medication, vitamins and 
low dose aspirin using the Independent samples t-test or one-way ANOVA. If significant associations 
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were identified, those confounders were also included in the multivariable logistic regression analysis. 
Pearson’s correlation was used to assess the correlation between the number of anti-VEGF injections 
a patient had received and percentage of leukocyte subsets. Data were presented as mean ± standard 
deviation (SD) calculated from untransformed variables even if the statistical analysis was performed on 
transformed variables. P values < 0.05 were considered statistically significant.
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